Blue Trust Inc’s Cellectis CLLS Stock Holding History

Blue Trust Inc’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-48	Closed	–	–	2070
2023 Q2	$0	Buy	+48	New	+$92	﹤0.01%	2089

Other funds holding CLLS

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Blue Trust Inc's CLLS Position: Q3 2023 in Review

Blue Trust Inc sold out of Cellectis (CLLS) in Q3 2023, closing a stake of 48 shares.

Blue Trust Inc first reported a position in CLLS in Q2 2023 and held it in 1 quarter. The position peaked at $0 in Q2 2023. 31 funds tracked by Wall St. Rank hold CLLS as of Q3 2023.

Blue Trust Inc reported no remaining Cellectis position as of Q3 2023 after selling out during the quarter.
Blue Trust Inc sold 48 Cellectis shares in Q3 2023.
Blue Trust Inc first reported a position in Cellectis in Q2 2023 and held it in 1 quarter.
Blue Trust Inc's Cellectis position peaked at $0 in Q2 2023.
31 funds tracked by Wall St. Rank held Cellectis as of Q3 2023.

Based on Blue Trust Inc's 13F filing for Q3 2023, filed 11 Oct 2023.